Non-System-Specific Biopharmaceuticals

AstraZeneca PLC

Bernstein Maintains Buy Rating on AstraZeneca

AstraZeneca CFO Submits Form 144 to Sell 15,000 Restricted Shares

Berenberg Bank Reiterates Buy Rating on AstraZeneca

DZ Bank Analyst Maintains Hold Rating on AstraZeneca

AstraZeneca Announces Positive Results for Bax24 in Phase III Clinical Trial for Resistant Hypertension

AstraZeneca and J Sainsbury Report Q3 Revenue Growth, Maintain Guidance and Increase Dividends

AstraZeneca Reports 11% YoY Revenue Growth in First Nine Months of 2025, Oncology Segment Up 16%

AstraZeneca Q3 EPS Exceeds Estimates

Analysts Have Different Ratings for AstraZeneca Stock

AstraZeneca Reaffirms Commitment to Industry Standards

GLOBALT Investments LLC GA reduced holdings in AstraZeneca PLC

Baifentan Investment Management Acquired AstraZeneca Shares in Q2

Deutsche Bank downgrades AstraZeneca to sell

AstraZeneca Invests $4.5 Billion in Building a Large Pharmaceutical Plant in Virginia

AstraZeneca and Turbine Collaborate on AI-driven Virtual Biologics Experiments to Enhance ADC Discovery

AstraZeneca and Amgen's Tezspire receives positive CHMP recommendation for chronic rhinosinusitis in EU

AstraZeneca Conducting AZD0120 Clinical Trials for Refractory Systemic Lupus Erythematosus

AstraZeneca CFO Sells Company Shares

AstraZeneca Releases Latest Progress on Ravulizumab Clinical Study

AstraZeneca Q2 2025 Earnings Beat Estimates

Nwam LLC reduced its holdings in AstraZeneca PLC by 40.1% in Q2, now owning 7,036 shares valued at $535,000. Other institutional investors adjusted their positions, with some increasing their holdings. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and a target price of $86. AstraZeneca's recent earnings beat expectations, with a revenue increase of 12% year-over-year.

Market Beat

Astrazeneca

AstraZeneca PLC $AZN Shares Sold by Nwam LLC

Bernstein Remains a Buy on AstraZeneca (AZN)

Tip Ranks

Bernstein Remains a Buy on AstraZeneca (AZN)

Sarin Aradhana, CFO of Astrazeneca Plc [AZN], filed a Form 144 with the SEC on November 12, 2025, to sell 15,000 shares of restricted securities. The filing allows the sale of shares within 90 days, facilitated by Morgan Stanley Smith Barney LLC. This is a standard procedure for selling restricted stock.

Reuters

CFO Sarin Files To Sell 15,000 Of Astrazeneca Plc [AZN]

Deutsche Bank analyst Emmanuel Papadakis has maintained a Sell rating on AstraZeneca (AZN) with a price target of £105.00. Papadakis, a 4-star analyst with a 53.29% success rate, focuses on the Healthcare sector. The current analyst consensus on AstraZeneca is a Moderate Buy, with an average price target of £114.97.

Deutsche Bank  Remains a Sell on AstraZeneca (AZN)

Berenberg Bank has reaffirmed its Buy rating on AstraZeneca (AZN) with a price target of £145.00, while the shares closed at £13,466.00. Analyst Luisa Hector, noted for her 4-star rating and 64.52% success rate, highlights a Moderate Buy consensus for AstraZeneca, with an average price target of £14,197.23, indicating a potential upside of 5.43%. Bernstein also maintains a Buy rating with a £180.00 target.

Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)

AstraZeneca shares hit a record 134.6 pounds, up 2.5% after strong Q3 earnings. The stock's value is now about 203.3 billion pounds, boosted by a U.S. drug-pricing deal.12AstraZeneca announced a deal on October 10, 2025, with the White House to reduce Medicaid drug prices, aligning them with those in other developed nations amid tariff negotiations.3

TradingView

Key facts: AstraZeneca shares reach record 134.6 pounds; U.S. drug deal announced

RHHBY

Find insight on AstraZeneca, Pfizer, Roche and more in the latest Market Talks covering Health Care.

Pfizer

Roche

Health Care Roundup: Market Talk

AstraZeneca (LSE:AZN) shares have gained about 5% over the past month and 26.7% year-to-date, reflecting strong revenue and earnings growth. The current market price of £134.66 is below the fair value estimate of $144.38, indicating potential upside. However, risks from patent expiries and biosimilar competition loom. AstraZeneca trades at a high price-to-earnings ratio of 28.5, above industry averages, raising concerns about whether growth expectations are already priced in. Investors are encouraged to consider both the growth potential and associated risks before making decisions.

Simplywall

AstraZeneca (LSE:AZN): Unpacking Valuation After Strong Share Price Gains and Long-Term Growth Signals

The FTSE 100 reached a new intraday high on November 11, driven by a declining pound and strong performance from AstraZeneca, which hit a record high. UK labor market data showed rising unemployment at 5.0%, exceeding forecasts, and sluggish wage growth, raising expectations for potential interest rate cuts by the Bank of England. Vodafone shares rose 5% after revising earnings projections, while Croda International shares fell nearly 4% following a downgrade by Jefferies. Overall, the FTSE 100 index rose by 0.98%.

Talkmarkets

Vodafone 

The FTSE Finish Line - Tuesday, Nov. 11

The FTSE 100 reached a record high, rising 0.8% as the pound weakened due to rising UK unemployment at 5%, the highest in four years. AstraZeneca hit an all-time high, driven by strong quarterly results. Vodafone shares climbed 5.5% after a strong performance in Germany, while media stocks gained 2.7%. However, Hilton Food's shares fell 22.5% amid profit growth challenges. The Bank of England may consider a rate cut in December as wage growth slows and labor market slack increases.

FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines

This week we will focus on star companies in various fields such as technology, catering, and pharmaceuticals.

AstraZeneca PLC $AZN Shares Sold by Nwam LLC

Bernstein Remains a Buy on AstraZeneca (AZN)

CFO Sarin Files To Sell 15,000 Of Astrazeneca Plc [AZN]

Deutsche Bank Remains a Sell on AstraZeneca (AZN)

Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)

Earnings Preview | A new round of 'Earnings Storm' is coming💥